RayThera focuses on discovering and advancing small-molecule therapies targeting inflammation across a range of ...

Biogen Inc. (BIIB) is a leading biotechnology company focused on discovering, developing, and delivering therapies for neurological, neurodegenerative, autoimmune, and rare diseases. Headquartered in ...

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q1 therapeutics ...

Biogen Stock Performance Snapshot Biogen (BIIB) has drawn investor attention after a recent move in its share price, with the ...

Biogen's MS drugs and Spinraza face mounting competition, pressuring overall sales growth. New launches like Leqembi, Skyclarys, and Zurzuvae delivered strong sequential gains. Despite rising new-drug ...

Biogen (BIIB) shares recorded their fifth consecutive day of increases, accumulating a total return of 14% during this span. The company’s market value has increased by approximately $3.3 billion over ...

Prominent biotech Biogen (NASDAQ: BIIB) loomed large on the stock market on Wednesday. It published its latest set of quarterly earnings, and investors greeted the estimates-beating numbers by piling ...

In August, the U.S. Food and Drug Administration (FDA) stated that it is requiring an additional MRI scan for Alzheimer's patients receiving Leqembi (lecanemab), citing safety concerns over a rare but ...

Healthcare company Biogen (NASDAQ: BIIB) wasn't looking very healthy on the stock market on Monday. Investors traded out of its shares after learning that the company plans to book a hefty charge in ...

View Biogen Inc. BIIB stock quote prices, financial information, real-time forecasts, and company news from CNN.

Biogen (BIIB) receives a hold rating as Leqembi sales may begin to sag, although it is possible new drug approvals may make up some of the difference. Eisai's claim that Leqembi delays the progression ...

Is Biogen (NASDAQ: BIIB) about to be acquired? One news article published on Wednesday reported that this is a possibility. As a result, the company's shares shot up almost 10% higher on the day. It ...